O1-04-05: Six-month Cerebral Metabolic Declines in Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Elderly Normal Control Groups: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

Kewei Chen,Eric M. Reiman,Gene E. Alexander,Wendy Lee,Cole Reschke,Oded Smilovici,Dan Bandy,Michael W. Weiner,Robert A. Koeppe,William J. Jagust

DOI: https://doi.org/10.1016/j.jalz.2007.04.081

2007-01-01

Abstract:In a previous FDG PET study, we found that patients with Alzheimer's disease (AD) had one-year declines in the regional cerebral metabolic rate for glucose (CMRgl), and we used that information to estimate the number of patients needed to evaluate putative disease-slowing treatments in one-year clinical trials (Alexander et al, 2002). To characterize approximately six-month CMRgl declines in patients with AD, patients with amnestic mild cognitive impairment (MCI) and elderly normal controls (NC), and to estimate the number of AD and MCI patients needed to evaluate a putative disease-slowing treatment in a six-month clinical trial, using PET images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\ADNI). Baseline and approximately six-month follow-up ADNI PET images were compared in separate analyses of 16 AD patients, 27 MCI patients and 27 NC using SPM5. Using the atlas coordinate with the maximally significant CMRgl decline in the respective AD and MCI comparison, power analyses were performed to estimate the number of patients needed to evaluate a putative primary prevention therapy in a six-month multi-center clinical trial. There was a trend for approximately six-month MMSE declines in the AD patients (P=0.06) and MCI patients (P=0.06) but not in the NC (P=0.86). The AD patients had six-month CMRgl declines in left temporal, parietal and precuneus regions (maximal reduction 3.0%), the MCI patients had six-month CMRgl declines in bilateral temporal, right parietal and right frontal regions (maximal reduction 2.0%), and the NC had had six-month declines in the left temporal cortex (P<0.001, uncorrected for multiple comparisons). Using the maximal, left temporal CMRgl declines in each patient group, we estimate the need for at least 224 AD patients or 642 MCI patients per treatment arm to detect a putative disease-slowing treatment efficacy to reduce six-month CMRgl declines by 25% with 80% power (one-tailed P=0.005, uncorrected for multiple comparisons) in a multi-center clinical trial. This study provides preliminary information about six-month CMRgl declines in AD and MCI patients and a preliminary estimate of the number of patients needed to detect CMRgl effects in six-month clinical trials of putative disease-slowing treatments.